secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-257347
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028
--------------------------------------------------------------------------------

- Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.
- On track to report topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025.
- Cash, cash equivalents and marketable securities of $943.1M as of Sept 30, 2025; expected runway into 2028.
- Q3 2025 net loss of $122.4M, R&D expenses $83.8M, G&A expenses $28.9M.
- Presented preliminary data for neladalkib in ALK-positive solid tumors at ESMO and preclinical data for NVL-330 in HER2-altered NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/0001193125-25-257347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525257347/nuvl-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-257347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer